Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling.

导出 OA

翻译打印收藏纠错

作者： Zhipeng,Su ^[1] ; Shengnan,Han ^[2] ; Qiumei,Jin ^[2] ; Ningning,Zhou ^[3] ; Junwan,Lu ^[2] ; Fugen,Shangguan ^[2] ; Shiyi,Yu ^[2] ; Yongzhang,Liu ^[2] ; Lu,Wang ^[2] ; Jianglong,Lu ^[2] ; Qun,Li ^[2] ; Lin,Cai ^[1] ; Chengde,Wang ^[1] ; Xiaohe,Tian ^[1] ; Lingyan,Chen ^[1] ; Weiming,Zheng ^[4] ; Bin,Lu ^[2]

作者单位： Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China. ^[1] Protein Quality Control and Diseases Laboratory, Key Laboratory of Medical Genetics of Zhejiang Province, Key Laboratory of Laboratory Medicine, Ministry of Education of China School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. ^[2] Department of Pathology, The Second Hospital of Jiaxing, Jiaxing University, Jiaxing, 314000, China. ^[3] Huaxi MR Research Center (HMRRC), Department of Radiology, Functional and molecular imaging Key Laboratory of Sichuan Province, West China Hospital of Sichuan University, Chengdu, 610041, China. ^[4] Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China. zhwm61@126.com. ^[5] Protein Quality Control and Diseases Laboratory, Key Laboratory of Medical Genetics of Zhejiang Province, Key Laboratory of Laboratory Medicine, Ministry of Education of China School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China. lubmito@wmu.edu.cn. ^[6]